February 15, 2019, Medscape 

The treatment of HER2-positive, early stage breast cancer has taken "one more step toward personalized medicine and reduced mortality" thanks to the results of the KATHERINE trial, according to Daniel Hayes, MD, a medical oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor. He says the trial is a "game changer" for patients who have residual disease after initial drug treatment and surgery, in an editorial published online in the New England Journal of Medicine. 

Read more.